Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure 7 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
  1. Home
  2. Publications
  3. Supplementary Figure 7 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer

Supplementary Figure 7 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer

Authors:
  • DKDian Kortleve
    Dian Kortleve
  • DHDora Hammerl
    Dora Hammerl
  • MBMandy van Brakel
    Mandy van Brakel
  • RWRebecca Wijers
    Rebecca Wijers
  • DRDaphne Roelofs
    Daphne Roelofs
  • KKKim Kroese
    Kim Kroese
  • MTMieke M. Timmermans
    Mieke M. Timmermans
  • CLChen-Yi Liao
    Chen-Yi Liao
  • SHShaozhuo Huang
    Shaozhuo Huang
  • ATAnita Trapman-Jansen
    Anita Trapman-Jansen
  • RFRenée Foekens
    Renée Foekens
  • JMJustine Michaux
    Justine Michaux

Open Access
Publisher website
Google Scholar
  • 17 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/2159-8290.32700226
Abstract
The extent of recognition of the ROPN1 target by FLY-1A TCR T cells correlates with level of expression.
Keywords
  • BREAST CANCER
  • ENGINEERING
  • GENE TECHNOLOGIES
  • IMMUNOLOGY
  • TUMOR ANTIGENS/NEOANTIGENS
  • TUMOR IMMUNOLOGY ANIMAL MODELS
  • IMMUNOTHERAPY
  • CELLULAR IMMUNOTHERAPY
  • ENGINEERED/CAR T CELLS
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.